Trial Profile
The impact of 18 weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC) on skeletal muscle composition of female breast cancer patients.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker
- 06 Jun 2012 New trial record